{"entity":{"id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","aka":[],"tldr":"A phase 1/2 trial of SLN124 in myeloproliferative neoplasms, run by Silence Therapeutics plc, active and no longer recruiting.","summary":"Study to Assess SLN124 in Patients With Polycythemia Vera is a phase 1/2 interventional study registered as NCT05499013 by Silence Therapeutics plc, with 69 participants enrolled, started 2023-01-26 and due to reach its primary completion in 2026-09. Interventions recorded: SLN124 and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05499013","url":"https://clinicaltrials.gov/study/NCT05499013"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05499013","phase":"1/2","setting":"Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera","sponsor":"Silence Therapeutics plc","enrolled":69,"outcomes":[]},"route":"/trials/nct05499013/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}]}}